Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?

CorMedix (CRMD) closed the last trading session at $9.99, gaining 12.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.20 indicates a 52.2% upside potential. The average comprises five short-term price targets ranging from a low of $9 to a high of $19, with a standard deviation of $4.15. While the lowest estimate indicates a decline of 9.9% from the current price level, the mo ...